Investigating Curcumin Phytocompounds as Prospective Parkinson's Disease Therapeutic Agents: A Computational Method that Targets LRRK2 Protein
Abstract
Objective: Parkinson’s Disease is the second stage predominant neurodegenerative illness. Primary aetiology is still unknown. One of the biggest battlegrounds in modern medicine is discovering the cause of Parkinson’s disease (PD), as well as the hunt for palliative treatments and, if feasible, a cure. The objective of this work is to identify the phytocompounds from curcumin (curcuma longa) for the treatment of PD. Curcumin, a well-researched phytochemical, has been suggested to have potential therapeutic benefits for Parkinson's disease treatment. So the target protein LRRK2 was used in the computational method for novel drug development to facilitate molecular docking against phytochemical derivatives of curcuma longa. The pharmacological characteristics and the therapeutic analysis of the same was investigated. Methods: In this study, computational methods were used to evaluate the ability of various curcumin plant compounds to inhibit the target protein LRRK2. Detailed docking of proteins using various tools such as PDB, PubChem, IMPAAT, ADME, ADMET lab 2.0, PyRx, BIOVIA Discovery Studio Visualizer, PDB sum and EMBOSS pep window. Result: The docking test results showed that the ligands chosen in this study have the highest binding affinities to each LRRK2 protein. Conclusion: The ligands identified in this study can be used in the future to evaluate their effectiveness as inhibitors of Parkinson's disease. More in vitro and in vivo research can be conducted to assess these ligands' inhibitory potential and produce fresh therapeutic benefits for Parkinson's disease inhibitors. This research identified 28 compounds initially, of which 17 were ultimately chosen for their pharmacological properties. Subsequently, through an analysis of protein-ligand interactions and binding affinities, ar-Turmerone, alpha-Turmerone, Nerolidol, and Curcuphenol emerged as the most promising candidates for targeting LRRK2.
Keywords
Full Text:
PDFReferences
Di Maio, R., Hoffman, E. K., Rocha, E. M., Keeney, M. T., Sanders, L. H., De Miranda, B. R., Zharikov, A., Van Laar, A., Stepan, A. F., Lanz, T. A., Kofler, J. K., Burton, E. A., Alessi, D. R., Hastings, T. G., & Greenamyre, J. T. (2018). LRRK2 activation in idiopathic Parkinson's disease. Science translational medicine, 10(451), eaar5429. https://doi.org/10.1126/scitranslmed.aar5429
Noorafshan, A., & Ashkani-Esfahani, S. (2013). A review of therapeutic effects of curcumin. Current pharmaceutical design, 19(11), 2032–2046.
Rao, Shobha S., Laura A. Hofmann, and Amer Shakil. "Parkinson’s disease: diagnosis and treatment." American family physician 74.12 (2006): 2046-2054. https://pubmed.ncbi.nlm.nih.gov/17186710/
Zafar, S., & Yaddanapudi, S. S. (2023). Parkinson Disease. In StatPearls. StatPearls Publishing. https://pubmed.ncbi.nlm.nih.gov/29261972/
Sharma N, Gupta N, Orfali R, Kumar V, Patel CN, Peng J, Perveen S. Evaluation of the Antifungal, Antioxidant, and Anti-Diabetic Potential of the Essential Oil of Curcuma longa Leaves from the North-Western Himalayas by In Vitro and In Silico Analysis. Molecules. 2022 Nov 8;27(22):7664. doi: 10.3390/molecules27227664. PMID: 36431765; PMCID: PMC9695312.
Jin, T., Zhang, Y., Botchway, B. O. A., Zhang, J., Fan, R., Zhang, Y., & Liu, X. (2022). Curcumin can improve Parkinson's disease via activating BDNF/PI3k/Akt signaling pathways. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association, 164, 113091. https://doi.org/10.1016/j.fct.2022.113091
Marín I. (2006). The Parkinson disease gene LRRK2: evolutionary and structural insights. Molecular biology and evolution, 23(12), 2423–2433. https://doi.org/10.1093/molbev/msl114
Xiong, Y., Dawson, T. M., & Dawson, V. L. (2017). Models of LRRK2-Associated Parkinson's Disease. Advances in neurobiology, 14, 163–191. https://doi.org/10.1007/978-3-319-49969-7_9
Sehgal, S. A., Hammad, M. A., Tahir, R. A., Akram, H. N., & Ahmad, F. (2018). Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design. Current neuropharmacology, 16(6), 649–663. https://doi.org/10.2174/1570159
X16666180315142137
Zhou, H., Beevers, C. S., & Huang, S. (2011). The targets of curcumin. Current drug targets, 12(3), 332–347. https://doi.org/10.2174/138945011794815356
Anand, V. S., & Braithwaite, S. P. (2009). LRRK2 in Parkinson's disease: biochemical functions. The FEBS journal, 276(22), 6428–6435. https://doi.org/10.1111/j.1742-4658.2009.07341.x
Gonzalez-Hunt, C. P., Thacker, E. A., Toste, C. M., Boularand, S., Deprets, S., Dubois, L., & Sanders, L. H. (2020). Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease. Scientific reports, 10(1), 17293. https://doi.org/10.1038/s41598-020-74195-6
Gurib-Fakim A. (2006). Medicinal plants: traditions of yesterday and drugs of tomorrow. Molecular aspects of medicine, 27(1), 1–93. https://doi.org/10.1016/j.mam.2005.07.008
Petrovska B. B. (2012). Historical review of medicinal plants' usage. Pharmacognosy reviews, 6(11), 1–5. https://doi.org/10.4103/0973-7847.95849
Rim K. T. (2020). In silico prediction of toxicity and its applications for chemicals at work. Toxicology and environmental health sciences, 12(3), 191–202. https://doi.org/10.1007/s13530-020-00056-4
Kumari, U., & Tan, E. K. (2009). LRRK2 in Parkinson's disease: genetic and clinical studies from patients. The FEBS journal, 276(22), 6455–6463. https://doi.org/10.1111/j.1742-4658.2009.07344.x
Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A Review of Its Effects on Human Health. Foods (Basel, Switzerland), 6(10), 92. https://doi.org/10.3390/foods6100092
Peng, Y., Ao, M., Dong, B., Jiang, Y., Yu, L., Chen, Z., Hu, C., & Xu, R. (2021). Anti-Inflammatory Effects of Curcumin in the Inflammatory Diseases: Status, Limitations and Countermeasures. Drug design, development and therapy, 15, 4503–4525. https://doi.org/10.2147/DDDT.S327378
Dallakyan, S., & Olson, A. J. (2015). Small-molecule library screening by docking with PyRx. Methods in molecular biology (Clifton, N.J.), 1263, 243–250. https://doi.org/10.1007/978-1-4939-2269-7_19
Darvesh, A. S., Carroll, R. T., Bishayee, A., Novotny, N. A., Geldenhuys, W. J., & Van der Schyf, C. J. (2012). Curcumin and neurodegenerative diseases: a perspective. Expert opinion on investigational drugs, 21(8), 1123–1140. https://doi.org/10.1517/13543784.2012.693479Fu, W., Zhuang, W., Zhou, S., & Wang, X. (2015). Plant-derived neuroprotective agents in Parkinson's disease. American journal of translational research, 7(7), 1189–1202.
Park, H. A., & Ellis, A. C. (2020). Dietary Antioxidants and Parkinson's Disease. Antioxidants (Basel, Switzerland), 9(7), 570. https://doi.org/10.3390/antiox9070570
Donadio, V., Incensi, A., Rizzo, G., Fileccia, E., Ventruto, F., Riva, A., Tiso, D., Recchia, M., Vacchiano, V., Infante, R., Petrangolini, G., Allegrini, P., Avino, S., Pantieri, R., Mostacci, B., Avoni, P., & Liguori, R. (2022). The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study. Journal of neuropathology and experimental neurology, 81(7), 545–552. https://doi.org/10.1093/jnen/nlac034
Salman, M. M., Al-Obaidi, Z., Kitchen, P., Loreto, A., Bill, R. M., & Wade-Martins, R. (2021). Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases. International journal of molecular sciences, 22(9), 4688. https://doi.org/10.3390/ijms22094688
Koszła, O., Stępnicki, P., Zięba, A., Grudzińska, A., Matosiuk, D., & Kaczor, A. A. (2021). Current Approaches and Tools Used in Drug Development against Parkinson's Disease. Biomolecules, 11(6), 897. https://doi.org/10.3390/biom11060897
Miao, Z., Bai, J., Shen, L., & Singla, R. K. (2021). The Combination of Tradition and Future: Data-Driven Natural-Product-Based Treatments for Parkinson's Disease. Evidence-based complementary and alternative medicine : eCAM, 2021, 9990020. https://doi.org/10.1155/2021/9990020
DOI: https://doi.org/10.37591/rrjocb.v12i3.3394
Refbacks
- There are currently no refbacks.